The company blamed its Q2 content slate for the subscriber miss.Technologyread more
Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
The declaration comes days after a case of the virus was confirmed in the Congolese city Goma, which borders neighboring country Rwanda.Health and Scienceread more
Federal Judge William Pauley wrote in a court filing made public Wednesday that materials related to a campaign finance probe of Cohen should be unsealed — and denied a...Politicsread more
With increasing expectations that the U.S. Department of Justice may block the pending acquisition of health insurer Humana by Aetna, JPMorgan downgraded Friday shares of Humana to "neutral" from "overweight."
"We have long held that only HUM shares have material downside if the DOJ were to block the pending acquisition by Atena," JP Morgan's Gary Taylor said in a report Friday.
The probability of a deal approval has declined well below 50/50 chance, Taylor said. If the deal were not to happen, Humana's shares could fall to a range of as low as $115 to $125, the analyst said.
The rival companies were scheduled to meet Assistant Attorney General William Baer Friday to discuss "significant concerns" with the deal, reported trade publication MLex, citing unnamed sources.
The regulators' concerns are focused on whether the deal will limit consumer choices for Medicare Advantages health plans for the elderly, according to reports.
If regulators challenge the acquisition, Aetna will need to decide if it wants to litigate the Justice Department's decision. Even if it does, and the deal still falls through, Aetna will owe a $1 billion pretax termination fee to Humana.
But for Wedbush Securities analyst Sarah James, she is confident that the Aetna deal will go through.
"We're 80 to 90 percent confident that the Aetna deal is going to go through," she told told CNBC's "Power Lunch " Friday.
She added, the results of the DOJ meeting could result in an update regarding the next steps for the companies to take and what a divestiture profile might look like.
"We expect stocks to move on that," she said.
Humana's stock has fallen about 11 percent this year, and were recently trading at $158.15, down 2.82 percent, or $4.59. Taylor also slashed his price target for Humana shares to $150 from $196.